The Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) by 11 companies/universities/institutes. The top development phase for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) is phase ii with seven drugs in that stage. The Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline products market are: Bristol-Myers Squibb, GSK and Merck.
The key targets in the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline products market include Toll Like Receptor 7 (TLR7), Toll Like Receptor 8 (CD288 or TLR8), and Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2).
The key mechanisms of action in the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline product include Toll Like Receptor 7 (TLR7) Antagonist with two drugs in Phase II. The Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline products include four routes of administration with the top ROA being Subcutaneous and three key molecule types in the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline products market including Small Molecule, and Monoclonal Antibody.
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) overview
Chronic Cutaneous Lupus Erythematosus also known as discoid lupus is a group of autoimmune disorders affecting the major areas of skin that can be associated with SLE. CLE is classified as acute, subacute, intermittent, and chronic. Although the cause is unknown major concerns are genetic, innate, and adaptive immune responses, smoking, exposure to sun, and medications. Upon physical examination round, coin-shaped lesions are observed specifically butterfly rash over cheeks that can be itchy or non-itchy. A skin biopsy is done for diagnosis. If untreated it can result in CKD that leads to transplantation, anemia, immunological effects, CNS effects seizures can be seen. Steroids are primary regimens given topically or through systemic route and symptomatic treatment. Prevention is decreased exposure to sun, or triggering factors, use of sunscreen lotion and vitamin D supplements recommended.
For a complete picture of Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
